The therapeutic community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s exhibiting significant efficacy in clinical trials for addressing obesity. Unlike some available weight loss approaches, retatrutide appears to deliver a significant substantial decrease in body mass and enhance metabolic healt